Cargando…
Safety and effectiveness of ferric citrate hydrate in serum phosphorus management of patients with chronic kidney disease: a long-term, real-world, observational, post-marketing surveillance study
BACKGROUND: Ferric citrate hydrate (FC) is an oral iron-based phosphate binder that is used to treat hyperphosphatemia in patients with chronic kidney disease (CKD). This post-marketing surveillance study was performed to investigate the long-term safety and effectiveness of FC. METHODS: This prospe...
Autores principales: | Yokoyama, Keitaro, Hashimoto, Teruo, Okuda, Yuri, Matsumoto, Yu, Ito, Kyoko, Yamada, Ryoichi, Susai, Hiroyuki, Nishino, Noriaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203387/ https://www.ncbi.nlm.nih.gov/pubmed/35258721 http://dx.doi.org/10.1007/s10157-022-02204-1 |
Ejemplares similares
-
Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study
por: Yokoyama, Keitaro, et al.
Publicado: (2019) -
Ferric citrate hydrate is associated with a reduced cost of drugs and a smaller change in red blood cell distribution width
por: Ito, Kyoko, et al.
Publicado: (2022) -
Iron absorption and phosphate-lowering effects of ferric citrate hydrate are not influenced by gastric acid secretion inhibitors in patients with chronic kidney disease: a retrospective post hoc analysis
por: Ito, Kyoko, et al.
Publicado: (2022) -
Ferritin Elevation and Improved Responsiveness to Erythropoiesis-Stimulating Agents in Patients on Ferric Citrate Hydrate
por: Yokoyama, Keitaro, et al.
Publicado: (2017) -
Oral Ferric Citrate Hydrate Associated With Less Oxidative Stress Than Intravenous Saccharated Ferric Oxide
por: Nakayama, Masaaki, et al.
Publicado: (2017)